Bernd Meibohm, Ph.D. is a Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN. He received his B.S. in pharmacy and Ph.D. in pharmaceutics from the Technical University Carolo-Wilhelmina, Braunschweig, Germany. After completion of a clinical pharmacology research fellowship at the University of Florida in 1997, he joined the faculty of the University of South Carolina, and in 1999 the University of Tennessee. Dr. Meibohm’s scientific interests include pulmonary infectious and inflammatory diseases, pediatric pharmacotherapy and the application of quantitative modeling and simulation techniques in preclinical and clinical drug development, with specific focus on therapeutic proteins. His research work has attracted more than $6 million in extramural funding as principal and co-investigator and has resulted in over 100 scientific papers and book chapters, three textbooks, 140 abstracts, and over 120 invited scientific presentations to national and international audiences. Dr. Meibohm is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and American College of Clinical Pharmacology (ACCP). He was the 2010 Chair for the ‘Pharmacokinetics, Pharmacodynamics and Drug Metabolism’ (PPDM) section of AAPS, and currently serves as President‑Elect for the American College of Clinical Pharmacology (ACCP). Dr. Meibohm is also serving as associate editor for The AAPS Journal, as section editor for ‘Pharmacokinetics and Pharmacodynamics’ for the Journal of Clinical Pharmacology, and is a member of the editorial boards of the Journal of Pediatric Pharmacology and Therapeutics, the Journal of Pharmacokinetics and Pharmacodynamics, Les Annales Pharmaceutiques Françaises and Die Pharmazie.
Focus Areas: Preclinical and Clinical Pharmacology | Pharmacokinetics | Pharmacodynamics | Pharmacometrics | Systems Pharmacology
Skills and Expertise: Drug Development | Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling and Simulation | Physiologic PK/PD Modeling | Population Pharmacokinetics | Nonlinear Mixed Effects Modeling | Therapeutic Proteins | Monoclonal Antibodies | Immunogenicity | Pediatric Pharmacotherapy